Brief: Palatin Technologies Phase 2 Clinical Study Expected To Begin Mid-Calendar Year 2024
02/05/2024 12:43
May 2 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THE
CO-ADMINISTRATION OF BREMELANOTIDE WITH TIRZEPATIDE (GLP-1) FOR
THE TREATMENT OF OBESITY
* PALATIN TECHNOLOGIES INC: TOPLINE DATA EXPECTED BY
CALENDAR
YEAR-END 2024
* PALATIN TECHNOLOGIES INC: PHASE 2 CLINICAL STUDY EXPECTED
TO
BEGIN IN MID-CALENDAR YEAR 2024
Source text for Eikon: ID:nPnbhdqyFa
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity